Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation

NCT ID: NCT00903929

Last Updated: 2016-05-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-12-31
• Study Completion Date: 2015-12-31

Brief Summary

Patients who undergo total body irradiation (TBI) for stem cell transplantation have prolonged periods of low counts of specific blood cells called platelets. These low platelets counts can cause bleeding and infection. Thus far, no drug is available for use to speed the recovery of platelets, and therefore transfusions are often necessary.

The purpose of this study is to test the safety of a drug called eltrombopag in patients who have received TBI. The investigators want to find out what effects, good or bad, it has on people with low platelet counts due to treatment with TBI. The investigators will also be testing how well eltrombopag may work at different doses and determine if this drug speeds up the recovery of the platelets.

Conditions

Thrombocytopenia; Acute Radiation Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Eltrombopag

Group Type: EXPERIMENTAL

Eltrombopag

Intervention Type: DRUG

dose escalation

Interventions

Eltrombopag

dose escalation

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18

2. Able to give written informed consent for a clinical trial

3. Scheduled to undergo an autologous or an allogeneic stem cell transplantation from a sibling, related donor, or unrelated donor using a conditioning regimen containing at least 400 cGy TBI

4. Transplantation is being performed for one of the following medical conditions:

• Acute myelogenous leukemia
• Acute lymphoblastic leukemia
• Chronic myelogenous leukemia in chronic, accelerated, or blastic phase
• Myelodysplastic syndrome
• Myeloproliferative diseases such as chronic myelomonocytic leukemia, agnogeneic myeloid metaplasia with myelofibrosis, polycythemia vera, or essential thrombocythemia
• Hodgkin's lymphoma
• Non-Hodgkin's lymphoma
• Multiple myeloma
• Chronic lymphocytic leukemia
• Other malignancies or marrow disease such as aplastic anemia where transplant would be appropriate with approval of principal investigator

5. Patients with therapy-related AML or MDS may be included if their prior malignancy has been in remission for at least 12 months. If the remission is less than 12 months, approval of the principal investigator is required. Entry could be allowed if the malignancy is controlled and not expected to relapse e.g. localized prostate cancer treated with XRT.

6. Patients must meet all other pre-transplantation criteria of the transplant center including acceptable tests of heart, liver, kidney, and lung function (Standard screening for HSCT per PI, and co-investigators).

7. Karnofsky performance status must be ≥70%.

Exclusion Criteria

1. TBI dose less than 400 cGY

2. Cord blood transplantation

3. HIV infection

4. Pregnancy or breastfeeding

5. Creatinine or bilirubin or ALT or AST greater than two times the upper limit of normal, unless the abnormal bilirubin is due to Gilbert's syndrome

6. Active infection requiring systemic antibiotic therapy with antibacterial, antifungal, or antiviral agents

7. Concomitant enrollment in another therapeutic clinical study except with PI approval

8. Must not have previously received eltrombopag

9. Patients with moderate or severe liver disease (ALT, AST, or bilirubin ≥ 2X the upper limit of normal, unless the abnormal bilirubin is due to Gilbert's syndrome) will be excluded

10. Patients with high risk of thromboembolism based on genetic syndromes , or past thromboembolic disease in the past 6 months will be excluded from the study, with the exception of those with catheter related clots

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jane Liesveld

OTHER

Sponsor Role: lead

Responsible Party

Jane Liesveld

Professor M&D-Hematology/Oncology

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Yuhchyau Chen, MD,PhD

Role: STUDY_DIRECTOR

University of Rochester

Jane Liesveld, MD

Role: PRINCIPAL_INVESTIGATOR

University of Rochester

References

Liesveld JL, Phillips GL 2nd, Becker M, Constine LS, Friedberg J, Andolina JR, Milner LA, DeBolt J, Smudzin T, Hyrien O, Erickson-Miller CL, Johnson BM, Dawson KL, Chen Y. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013 Dec;19(12):1745-52. doi: 10.1016/j.bbmt.2013.10.002. Epub 2013 Oct 8.

Reference Type: DERIVED

PMID: 24120380 (View on PubMed)

Other Identifiers

RSRB00028043

Identifier Type: -

Identifier Source: org_study_id